| __timestamp | Eli Lilly and Company | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 4326000 |
| Thursday, January 1, 2015 | 6533000000 | 226206000 |
| Friday, January 1, 2016 | 6452000000 | 94391000 |
| Sunday, January 1, 2017 | 6588100000 | 53821000 |
| Monday, January 1, 2018 | 5975100000 | 35463000 |
| Tuesday, January 1, 2019 | 6213800000 | 46456000 |
| Wednesday, January 1, 2020 | 6121200000 | 71318000 |
| Friday, January 1, 2021 | 6431600000 | 135256000 |
| Saturday, January 1, 2022 | 6440400000 | 102708000 |
| Sunday, January 1, 2023 | 6941200000 | 129620000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust SG&A management over the past decade. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady trend, peaking in 2023 with a 5% increase from the previous year. In contrast, ImmunityBio, Inc., a relatively newer player, has experienced more volatility. Their SG&A expenses surged by over 5000% from 2014 to 2023, reflecting their aggressive growth strategy. This comparison highlights the strategic differences between established giants and emerging innovators. As Eli Lilly focuses on maintaining efficiency, ImmunityBio invests heavily in expansion, each approach offering unique insights into their operational priorities.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.